MA54542A - Compositions de sparsentan amorphe - Google Patents

Compositions de sparsentan amorphe

Info

Publication number
MA54542A
MA54542A MA054542A MA54542A MA54542A MA 54542 A MA54542 A MA 54542A MA 054542 A MA054542 A MA 054542A MA 54542 A MA54542 A MA 54542A MA 54542 A MA54542 A MA 54542A
Authority
MA
Morocco
Prior art keywords
sparsentan
amorphous
compositions
sparsentan compositions
amorphous sparsentan
Prior art date
Application number
MA054542A
Other languages
English (en)
Inventor
James Francis Hulvat
Dainius Macikenas
Kale Ruby
Xiangming Wu
Original Assignee
Travere Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Travere Therapeutics Inc filed Critical Travere Therapeutics Inc
Publication of MA54542A publication Critical patent/MA54542A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA054542A 2018-12-21 2019-12-20 Compositions de sparsentan amorphe MA54542A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862783947P 2018-12-21 2018-12-21

Publications (1)

Publication Number Publication Date
MA54542A true MA54542A (fr) 2021-10-27

Family

ID=69187971

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054542A MA54542A (fr) 2018-12-21 2019-12-20 Compositions de sparsentan amorphe

Country Status (12)

Country Link
US (1) US20220048900A1 (fr)
EP (1) EP3897834A1 (fr)
JP (1) JP2022514569A (fr)
KR (1) KR20210125994A (fr)
CN (1) CN114126712A (fr)
AU (1) AU2019404552A1 (fr)
BR (1) BR112021012226A2 (fr)
CA (1) CA3124127A1 (fr)
IL (1) IL284186A (fr)
MA (1) MA54542A (fr)
MX (1) MX2021007258A (fr)
WO (1) WO2020132594A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7524167B2 (ja) 2018-10-04 2024-07-29 トラビア セラピューティクス, インコーポレイテッド Iv型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
WO2022266370A1 (fr) 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan pour le traitement de la fibrose pulmonaire idiopathique
WO2023127853A1 (fr) * 2021-12-28 2023-07-06 株式会社アークメディスン Composé, antagoniste du récepteur de l'angiotensine ii de type 1 et composition pharmaceutique
JP2025183466A (ja) * 2022-11-11 2025-12-17 株式会社アークメディスン 化合物、エンドセリンa受容体拮抗剤、アンジオテンシンiiタイプ1受容体拮抗剤及び医薬組成物
JP2026508235A (ja) * 2023-02-24 2026-03-10 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 芳香環含有誘導体アンタゴニストの塩、その製造方法及び応用
CN118666826A (zh) * 2024-08-23 2024-09-20 成都臻拓医药科技有限公司 一种司帕生坦原料药的重结晶纯化方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
WO2001044239A2 (fr) * 1999-12-15 2001-06-21 Bristol-Myers Squibb Co. Biphenyl sulfonamides utilises comme doubles antagonistes des recepteurs de l'angiotensine et de l'endotheline
WO2010114801A1 (fr) * 2009-03-31 2010-10-07 Ligand Pharmaceuticals Inc. Formulation orale d'agonistes des récepteurs de l'endothéline et de l'angiotensine ii à base de diphénylsulfonamide pour traiter une pression sanguine élevée et une néphropathie diabétique
WO2010135350A2 (fr) * 2009-05-20 2010-11-25 Pharmacopeia, Llc Composes intermediaires de biphenyle et procedes pour la preparation d'un double antagoniste de recepteur d'angiotensine ii et d'endotheline
JP2019530713A (ja) 2016-10-13 2019-10-24 レトロフィン, インコーポレイテッド 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物

Also Published As

Publication number Publication date
CN114126712A (zh) 2022-03-01
MX2021007258A (es) 2021-08-16
JP2022514569A (ja) 2022-02-14
AU2019404552A1 (en) 2021-07-15
IL284186A (en) 2021-08-31
CA3124127A1 (fr) 2020-06-25
WO2020132594A1 (fr) 2020-06-25
US20220048900A1 (en) 2022-02-17
KR20210125994A (ko) 2021-10-19
BR112021012226A2 (pt) 2021-09-08
EP3897834A1 (fr) 2021-10-27

Similar Documents

Publication Publication Date Title
EP3722358A4 (fr) Composition
DK3697376T3 (da) Sammensætning
EP3823584A4 (fr) Composition détergente
EP3894163A4 (fr) Compositions de revêtement
DK3473674T3 (da) Polypropylensammensætning
DK3924443T3 (da) Compositions
EP3853332C0 (fr) Composition
EP3747978A4 (fr) Composition de graisse
EP3741810A4 (fr) Composition de silicone
EP3763805A4 (fr) Composition de graisse
EP3882323A4 (fr) Composition
EP3672944A4 (fr) Compositions de nettoyage
EP3936592A4 (fr) Composition de graisse
DK3840596T3 (da) Sammensætning
IL284186A (en) Amorphous sparsantan preparations
EP3871694A4 (fr) Composition
EP3897866C0 (fr) Composition antimicrobienne
DK4234656T3 (da) Sammensætninger
EP3898809C0 (fr) Composition de polypropylène
EP3981256A4 (fr) Composition
EP3954721A4 (fr) Composition
EP3941942A4 (fr) Composition
PT3765379T (pt) Composições
EP3999039A4 (fr) Compositions de prétomanide
DK3706724T3 (da) Orale rifamycin-sv-sammensætninger